ResMed Annual Filing Shows Higher Revenue, Operating Income, Net Income, and Diluted EPS Versus Prior Year

Bottom line

the filing is the annual report filed by RESMED INC (RMD) under 10-K for the twelve-month period the twelve months ended June 30, 2026, identified by CIK 0000943819 and accession 0000943819-26-000047; the prior-year comparative window is the twelve months ended June 30, 2025. The source material drawn on for this section is the "Cautionary Note Regarding Forward-Looking Statements" opening of Part I and the opening narrative of Item 1, supplemented by the consolidated financial-statement and supplementary-data section referenced as Item 8, the controls-and-procedures discussion at Item 9A, and the segment-information note at Note 13. These are the only references in the inventory that touch the periods, identity, and financial dimensions covered below; everything else (executive compensation, exhibits, security ownership, principal accountant fees, foreign-jurisdiction disclosures, and recent accounting changes) falls outside this section's scope and is not relied on here.

For the twelve-month window the twelve months ended June 30, 2026, the registrant reports Revenue from Contract with Customer, Excluding Assessed Tax of $5,653,443,000 USD, against a prior-year comparative of $5,146,327,000 USD for the twelve months ended June 30, 2025; the reported direction for this dimension is an increase on a positive-to-positive basis. Operating Income (Loss) is reported at $1,886,715,000 USD for the twelve months ended June 30, 2026, versus $1,685,363,000 USD for the twelve months ended June 30, 2025, with the authorized direction likewise an increase on a profit-to-profit transition. Net Income (Loss) Attributable to Parent is reported at $1,523,293,000 USD for the twelve months ended June 30, 2026, against $1,400,723,000 USD for the twelve months ended June 30, 2025, authorized as an increase on a profit-to-profit transition. Earnings Per Share, Diluted is reported at $10.43 per diluted share USD/SHARES for the twelve months ended June 30, 2026, versus $9.51 per diluted share USD/SHARES for the twelve months ended June 30, 2025, authorized as an increase on a profit-to-profit transition. Each of those four dimensions is profit on both windows, so the comparative language throughout this section is "higher than the prior period" and "a profit rather than a loss"; no window shows a loss, a swing, or a directional reversal.

The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

In aggregate the picture conveyed by the filing evidence for RESMED INC's twelve-month period is straightforward and uniformly favorable across the four reported dimensions: revenue, operating income, net income, and diluted EPS are each higher than the prior-year comparative, and each remains in profit on both windows. No dimension shows a decline, a swing from profit to loss, or a loss on either window. A complementary cross-check on the same profit-to-profit pattern is available in REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended-2026-06-30 Filing, which illustrates the same authorized direction on the same two dimensions.

Financial performance

The filing covers RESMED INC's period-ended-2026-06-30 annual report on 10-K under accession 0000943819-26-000047, with comparatives restated against the twelve months ended June 30, 2025 for the twelve-month view now reported as the twelve months ended June 30, 2026. The reporting perimeter reflects a two-segment structure — Sleep and Breathing Health, plus Residential Care Software — with segment detail supplied in the cited segment information note rather than restated within management's commentary. Readers evaluating performance should anchor their view on the four headline measures disclosed for the twelve-month period and the matching prior-year comparative, because the consolidated income statement is the only window through which year-over-year direction is explicitly authorized in the filing evidence.

Revenue from Contract with Customer, Excluding Assessed Tax moved from $5,146,327,000 in the prior twelve months to $5,653,443,000 in the current twelve months, an authorized year-over-year increase on a positive base. Operating Income (Loss) similarly shifted from $1,685,363,000 to $1,886,715,000, also an authorized increase on a profit base. The combination of those two authorized movements leaves the implied operating spread between revenue and operating income to be read directly from the catalogued values; the filing evidence does not separately quantify cost-of-revenue, research and development, or selling, general and administrative line items in this section's catalog, so any further decomposition of the operating gap is outside what the cited notes support here. Net Income (Loss) Attributable to Parent moved from $1,400,723,000 to $1,523,293,000, again an authorized increase, profit-to-profit. Earnings Per Share, Diluted moved from $9.51 per diluted share to $10.43 per diluted share, the same authorized increase, profit-to-profit, and is the cleanest summary of the bottom-line shift because it absorbs both the earnings change and any movement in the diluted share count that the filing reports elsewhere.

The filing evidence does not attribute this change to any single cause.

No quarterly direction, sequential comparison, or forward-looking guidance figure is present in this section's catalog, so any quarter-on-quarter movement or management outlook for the next twelve months is not stated in the evidence available to this section. The filing evidence contains no peer or industry comparison. Investors looking to benchmark these authorized increases against sector peers can pair this read with the parallel year-over-year profit-to-profit pattern documented for REINSURANCE GROUP OF AMERICA INC's higher revenue and net income filing, which illustrates the same direction-of-travel language applied to a different issuer and helps frame how a uniform profit-to-profit increase is presented in a Lizely-style write-up.

Operating drivers and segments

The company reports operating in two segments, the Sleep and Breathing Health segment and the Residential Care Software segment, with segment financial detail tied to the cited segment note within Item eight of the consolidated financial statements. Outside that note, the excerpt for this section does not expose segment-level revenue, segment-level operating profit, or a segment-versus-segment margin split, so an independent margin walk across the two segments cannot be reconstructed from the surfaced text alone. Top-line and consolidated operating-profit context, however, is present: the consolidated income statement shows Revenue from Contract with Customer, Excluding Assessed Tax of $5,653,443,000 USD for the twelve-month period the twelve months ended June 30, 2026, compared with $5,146,327,000 USD for the prior-year comparative the twelve months ended June 30, 2025, and Operating Income (Loss) of $1,886,715,000 USD for the current twelve-month period, compared with $1,685,363,000 USD for the prior-year comparative. The filing evidence contains no peer or industry comparison. Any commentary on which segment is leading or lagging margin therefore sits with the cited segment note rather than with the surfaced filing text.

Management frames the business as a global digital-health and cloud-connected medical-device franchise built around an AI-enabled software and device ecosystem, anchored historically in continuous positive airway pressure treatment for obstructive sleep apnea and extended into broader sleep and respiratory care, ventilation, diagnostics, masks and accessories, and dental devices. Residential Care Software is also presented as part of the platform through cloud-based applications and connected-care tools intended to support clinician workflows and patient adherence, with additional IDTF capability added via the prior VirtuOx transaction. The cautionary statement accompanying the filing lists expected future revenue and earnings, new product development and launches, new market entry, integration of acquisitions, strategic initiatives including divestitures, supply-chain and regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions as the recurring forward-looking themes management itself emphasises. The filing separately flags recent inorganic moves, such as the Noctrix Health acquisition in June of the period, as portfolio extensions into adjacent clinical areas, without quantifying their contribution in the surfaced text. Independent verification of those qualitative claims against the reported numbers is limited to the consolidated revenue and operating-income lines, since segment-level numbers, unit volumes, geographic splits, and acquisition contribution are not surfaced in the excerpt that supports this section.

The Sleep and Breathing Health segment and the Residential Care Software segment are the two operating groups management discloses, and segment financial information is referenced through the cited segment note under Item eight rather than reproduced in the surfaced excerpt. The consolidated twelve-month income statement shows revenue of $5,653,443,000 USD for the twelve months ended June 30, 2026, higher than the prior-year comparative of $5,146,327,000 USD for the twelve months ended June 30, 2025, alongside operating income of $1,886,715,000 USD for the current period, higher than $1,685,363,000 USD for the prior-year comparative. The filing evidence does not attribute this change to any single cause.

Management's own forward-looking language points to new product development, new product launches, new geographic and clinical markets, integration of recent acquisitions such as Noctrix Health, supply-chain dynamics, regulatory developments, and macroeconomic conditions as the themes it expects to drive results, while the cautionary statement also lists healthcare reform, geopolitical and tariff exposure, third-party actions, and competitive pressure among the risks that could push outcomes the other way. Independent cross-checks against those qualitative claims are constrained by what the surfaced excerpt discloses, so this section does not attempt to score management's narrative against segment-level data that the text does not expose. Readers can place this result alongside the kind of dual-window, revenue-plus-profit pattern shown in coverage such as REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended-2026-06-30 Filing, although that piece covers a different issuer and is offered here only as a structural comparison, not a peer benchmark.

Cash flow and capital

Across the twelve-month period, RESMED INC reported a healthy operating cash engine, with Net Cash Provided by (Used in) Operating Activities moving higher than the prior-year comparative on a positive-to-positive basis ($1,805,829,000 versus $1,751,588,000, both for the twelve-month period the twelve months ended June 30, 2026 against the twelve months ended June 30, 2025). Investing and financing activities both remained in negative territory, with Net Cash Provided by (Used in) Investing Activities and Net Cash Provided by (Used in) Financing Activities registering as uses of cash for the current twelve-month period at -$545,199,000 and -$1,007,029,000, respectively. The prior-year comparatives were also cash uses at -$200,045,000 and -$606,253,000 (both for the twelve months ended June 30, 2025); the authorized direction for each is decrease. Free cash generation, on the simple operating-minus-capex view, depends on the gap between $1,805,829,000 and $156,285,000; the underlying product splits are visible elsewhere in the filing only at the consolidated-cash-flow-statement level.

Capital expenditures — Payments to Acquire Property, Plant, and Equipment — are disclosed at $156,285,000 for the current twelve-month period the twelve months ended June 30, 2026, against $89,865,000 for the prior twelve-month period the twelve months ended June 30, 2025; the authorized direction here is an increase, with both years showing positive outflows. The filing evidence does not attribute this change to any single cause. Capital intensity read against installed-base growth therefore depends on revenue and gross-profit trajectory laid out in earlier sections of this 10-K for period-ended-2026-06-30.

Shareholder returns show stepped-up direct cash returns to shareholders. Payments of Dividends for the current twelve-month period the twelve months ended June 30, 2026 sit at $349,662,000, higher than the prior-year comparative $310,880,000 for the twelve months ended June 30, 2025, consistent with the authorized direction of an increase. Payments for Repurchase of Common Stock are reported at $700,037,000 for the twelve months ended June 30, 2026, versus $300,025,000 for the twelve months ended June 30, 2025, again with an authorized increase and both years positive. Combined with the financing-line movement, this points to a meaningful return-of-capital posture across the fiscal year.

The balance sheet snapshot at the balance sheet date of June 30, 2026 — drawn from Item 8 in this 10-K filing under 0000943819-26-000047 — shows Cash and Cash Equivalents, at Carrying Value of $1,469,234,000 and Accounts Payable, Current of $308,923,000, both anchoring the working-capital position. The filing evidence does not attribute this change to any single cause. Liquidity coverage relative to annual operating cash burn, debt service, dividends, repurchases, and capex is a derived view that the article does not compute; readers running that screen can pair the inputs above with the methods described in How to Calculate a Discounted Payback Period and the broader suite at Finance Calculators Insights. Net Cash Provided by (Used in) Financing Activities is captured at -$1,007,029,000 (the twelve months ended June 30, 2026) versus -$606,253,000 (the twelve months ended June 30, 2025), both negative with an authorized decrease direction. Counter-evidence in this dataset is limited because The filing evidence contains no peer or industry comparison. and The filing evidence does not disclose segment-level detail for this dimension. — readers should treat the operating-cash strength and step-up in returns as the dominant signals.

Peer and historical context

- In the filing under 10-K for period-ended-2026-06-30 (accession 0000943819-26-000047), RESMED INC reports its full-year results against the prior-year comparative, providing the only historical benchmark the filing itself supplies. - Revenue from Contract with Customer, Excluding Assessed Tax was $5,653,443,000 USD for the twelve months ended June 30, 2026, higher than the prior-year figure of $5,146,327,000 USD for the twelve months ended June 30, 2025; authorized direction for this line is increase, and the transition is positive to positive.

- Operating Income (Loss) was $1,886,715,000 USD for the twelve months ended June 30, 2026, higher than $1,685,363,000 USD for the twelve months ended June 30, 2025; authorized direction is increase, transition profit to profit. - Net Income (Loss) Attributable to Parent was $1,523,293,000 USD for the twelve months ended June 30, 2026, higher than $1,400,723,000 USD for the twelve months ended June 30, 2025; authorized direction is increase, transition profit to profit. - Net Cash Provided by (Used in) Operating Activities was $1,805,829,000 USD for the twelve months ended June 30, 2026, higher than $1,751,588,000 USD for the twelve months ended June 30, 2025; authorized direction is increase, with both periods positive.

- The consolidated statements also report Net Cash Provided by (Used in) Financing Activities and Net Cash Provided by (Used in) Investing Activities for the twelve months ended June 30, 2026 versus the twelve months ended June 30, 2025; the authorized direction on both lines is decrease, with current and prior periods both negative, so the gap between cash generation and cash absorption is simply left to the reader to interpret. - On the cash-out side, Payments for Repurchase of Common Stock, Payments of Dividends, and Payments to Acquire Property, Plant, and Equipment are each authorized as higher than the prior year on the twelve months ended June 30, 2026 versus the twelve months ended June 30, 2025, all positive on both sides — consistent with the pattern of higher operating cash flow alongside higher returns-of-capital and capex outlays.

- Reported historical comparisons are limited to those issued by RESMED INC itself; the filing contains no peer-set data, no industry composite, and no third-party benchmark. The filing evidence contains no peer or industry comparison. - Segment-level histories under the cited segment note (Note 13) are not disclosed at a granularity that supports an apples-to-apples peer view, so any segment-based cross-company comparison sits behind The filing evidence does not disclose segment-level detail for this dimension..

- The narrative portion of the filing describes ResMed's product portfolio spanning sleep-disordered breathing and chronic respiratory care (CPAP, bilevel, ventilation, humidifiers, masks, and the myAir application), but it does not translate that business mix into a quantified peer comparison or a market-share trend across years. - For investors who want a side-by-side earnings read against another healthcare-equipment issuer, a useful template is REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, which mirrors the same revenue-up, profit-up structure on RESMED INC's own balance sheet.

- For valuation follow-through on the kind of multi-year cash profile ResMed prints here, the framework in How to Calculate a Discounted Payback Period lets readers stress-test the higher capex and dividend outflows against the higher operating cash inflow without needing peer data. - The filing evidence does not attribute this change to any single cause.

Scenario analysis

- The conditional scenarios below translate the reported twelve-month figures filed by RESMED INC on 10-K for period-ended-2026-06-30 (accession 0000943819-26-000047, CIK 0000943819, ticker RMD) into three forward-looking branches. Each branch is anchored only to the audited direction the catalog authorizes and to the qualitative observations drawn from the cited note on segment information. No attempt is made here to size any branch in dollars or to assign probabilities. - Reported facts: Revenue from Contract with Customer, Excluding Assessed Tax is shown at $5,146,327,000 for the twelve months ended June 30, 2025 and at $5,653,443,000 for the twelve months ended June 30, 2026, with the catalog authorizing a higher reading in the current period. Net Income (Loss) Attributable to Parent is recorded at $1,400,723,000 for the prior twelve-month comparative and at $1,523,293,000 for the twelve months ended June 30, 2026, with the catalog again authorizing a higher reading in the current period and a profit-to-profit transition. - Management explanations: The narrative accompanying the filing describes a portfolio spanning sleep-disordered breathing and chronic respiratory care, including CPAP and bilevel systems, high-flow therapy, non-invasive and invasive ventilation, humidifiers, masks and accessories, the myAir patient engagement application with its Smart Comfort feature, and data systems for care providers. The cited note on segment information is referenced as the source of consolidated revenue and net income framing, and the narrative discusses COPD, OHS and neuromuscular-disease populations as the patient base the device and software portfolio is designed to serve. - Analyst inference: Because both the top line and the bottom line are authorized as higher year over year on a profit-to-profit basis, the base branch assumes that the existing sleep-and-breathing franchise continues to compound at a pace consistent with that authorized direction, with the myAir and Smart Comfort engagement layer cited in the filing supporting therapy-adherence economics in the background. The filing evidence does not attribute this change to any single cause. - The upside branch layers in the possibility that the cited note on segment information, combined with the broader device-and-software narrative, supports faster adoption of the high-flow therapy and non-invasive ventilation lines used in chronic respiratory care. If realized, this would lift the higher direction already authorized for both revenue and net income without altering the profit-to-profit transition. Counter-evidence to flag is that the filing does not disclose segment-level detail in the excerpt, so any segment skew is inferred rather than reported. The filing evidence does not disclose segment-level detail for this dimension. - The downside branch assumes that the authorized higher direction for revenue and net income proves fragile, for example through competitive pressure in the core sleep-disordered-breathing category, slower resupply cycles, or reimbursement headwinds in the chronic respiratory portfolio. In that case, the higher direction could compress toward a roughly flat reading and the profit-to-profit transition would be at risk of narrowing margins. Peer benchmarking that would normally discipline such a downside view is not present in the filing evidence. The filing evidence contains no peer or industry comparison. - A reader weighing the branches should treat the authorized direction and the profit-to-profit transition as the audited anchors and read the upside and downside layers as conditional paths whose drivers are not assigned by the filing. The thinness of the segment and peer signal means the scenarios differ more in the magnitude of the deviation from the authorized direction than in the sign of the movement.

LINKS:

Risks and what to watch

- Reported facts: For the twelve-month period, Revenue from Contract with Customer, Excluding Assessed Tax was $5,653,443,000 USD, compared with $5,146,327,000 USD for the prior-year comparative. Net Income (Loss) Attributable to Parent was $1,523,293,000 USD, compared with $1,400,723,000 USD for the prior-year comparative. Both top-line and bottom-line movements are authorized as increases, and the earnings transition is profit to profit, but the filing does not disclose the magnitude of the year-over-year shift in percentage terms, leaving readers to gauge the pace of growth from the absolute figures alone.

- Management explanations: The narrative around business strategy and clinical positioning (covering sleep apnea, COPD, OHS, neuromuscular disease, and Residential Care Software) describes demand drivers such as rising awareness of OSA, CSA, and COPD, the expansion of bilevel and NIV use in COPD, and digital and product technology integration including AI and ML. The filing frames these as long-term tailwinds but does not allocate them as the named reason for the twelve-month revenue or net income result. Consequently, the linkage from any single strategy element to the reported numbers is not stated.

- Analyst inference: Because the filing language is structural and forward-looking rather than retrospective, any attempt to attribute the year's results to a specific product, region, or customer cohort would be speculation; the consolidated statements do not present segment-level or geographic-level revenue or operating income for the period. The interest-expense line, share-repurchase pace, dividend pace, capital expenditure pace, and the operating, investing, and financing cash-flow outcomes (each authorized to a direction in the reported comparison table) are visible only at the consolidated level.

Readers can compare how those flow categories evolved year over year without re-deriving the numbers here. - Counter-evidence: The filing's own cautionary framing sits within Item 1A and the broader risk-factor discussion, where forward-looking statements are explicitly qualified and estimates-based content is flagged as such. That same risk-factor context is where any disagreement with the bull case on demand for sleep and breathing therapies would normally be disclosed, so its placement is the natural counterweight to the strategy narrative.

No item in the filing directly rebuts the reported revenue or net income figures. - Unknowns: The filing evidence does not disclose segment-level detail for this dimension, so a reader cannot see how Sleep and Breathing Health Devices, Residential Care Software, or any regional grouping contributed to the consolidated result. The filing also does not name a single driver of the year-over-year change in revenue or net income.

The filing evidence contains no peer or industry comparison, so relative performance against other medical-device or connected-health peers is not assessable from this document alone. - Metrics to watch next period: revenue growth versus the prior year, the trajectory of net income, operating cash flow generation, capital expenditure, share repurchases and dividends, and any updated disclosure of segment composition or Residential Care Software performance. Readers wanting a side-by-side example of how a different issuer presented a comparable profit-to-profit full-year result can review REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing for context, while keeping in mind that the filing evidence here does not attribute the change to any single cause.